MaxCyte Reports 15% Decline in Revenue for 2025, Expects Continued Headwinds in 2026
ByAinvest
Tuesday, Mar 24, 2026 5:49 pm ET1min read
MXCT--
MaxCyte reported a 15% decline in total revenue for 2025, to $33.0 million, and a 16% decline in Q4 revenue to $7.3 million. Core revenue fell 9% for the year and 22% in Q4. The company's instrument install base grew to 857 from 760 in 2024. MaxCyte's SPL revenue mix shifted due to customer program rationalization, with 47% of core business revenue coming from SPL customers in 2025, compared to 55% in 2024. The company launched a new research-focused electroporation system, ExPERT DTx, in February.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet